Found: 3
Select item for more details and to access through your institution.
(RTH05) Characterization of the Pharmacokinetics and Pharmacodynamics of Satralizumab, a Recycling Antibody, to Support Once-Every-4-Weeks Dosing in Patients with Neuromyelitis Optica Spectrum Disorder.
- Published in:
- International Journal of MS Care, 2020, v. 22, n. S2, p. 78
- By:
- Publication type:
- Article
(RTH01) Safety of Satralizumab Based on Pooled Data from Phase 3 Studies in Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD).
- Published in:
- International Journal of MS Care, 2020, v. 22, n. S2, p. 77
- By:
- Publication type:
- Article
(RTH02) Adolescents with Neuromyelitis Optica Spectrum Disorder Achieved Similar Exposures and Favorable Safety Profile When Treated with the Adult Satralizumab Dosing Regimen.
- Published in:
- International Journal of MS Care, 2020, v. 22, n. S2, p. 77
- By:
- Publication type:
- Article